As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo Nordisk ( NVO +0.47%) and Eli Lilly ( LLY +4.57%) slugging it out, while Pfizer ...
Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...
A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and Wegovy, is a step toward making them more affordable and accessible ...
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...
Novo Nordisk India and Emcure Pharma announced a strategic partnership on Monday to launch Poviztra (semaglutide injection ...
WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...
Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...
Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...
Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide ...
Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.
Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...
New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback